Estimating the time since discharge of spent cartridges: a logical approach fro interpreting the evidence

Estimating the time since discharge of a spent cartridge or a firearm can be useful in criminal situa-tions involving firearms. The analysis of volatile gunshot residue remaining after shooting using solid-phase microextraction (SPME) followed by gas chromatography (GC) was proposed to meet this objective. However, current interpretative models suffer from several conceptual drawbacks which render them inadequate to assess the evidential value of a given measurement. This paper aims to fill this gap by proposing a logical approach based on the assessment of likelihood ratios. A probabilistic model was thus developed and applied to a hypothetical scenario where alternative hy-potheses about the discharge time of a spent cartridge found on a crime scene were forwarded. In order to estimate the parameters required to implement this solution, a non-linear regression model was proposed and applied to real published data. The proposed approach proved to be a valuable method for interpreting aging-related data.

Permo-Triassic stratigraphy of the pelagonian zone in central Evia island (Greece)

A new subdivision of the pre-Jurassic Pelagonian Units in central Evia island is proposed these units are represented by syn- and post rift sequences, separated by a volcano-sedimentary episode. The syn-rift sequences comprise Permian siliciclastic sediments in Verrucano tectofacies, (Ano Mavropoulon Formation) and a small carbonate platform (Zigos Limestones) developed from the Permian to the Middle Anisian. The Ano Mavropoulon Fro, is subdivided into three members: the lower member (Permian s.l.) lying on the basement and characterised by medium-coarse elastic terrigenous sedimentation the middle member (Late Permian) Koprises limestones, made up of shallow-water limestones; the upper member (Latest Permian-Early Triassic) comprising elastic terrigenous and minor reworked carbonate sediments. A regional unconformity (earliest Triassic) separates the Zigos Lm. from the top of the Ano Mavropoulon Fm. The peritidal carbonates belonging to the Zigos Lm, have been subdivided into three lithofacies ranging in age from Spathian to Pelsonian (late Early Triassic to Middle Anisian). The volcanic episode is well constrained in all the Pelagonian domain. In central Evia, it has been dated from Middle Anisian to Early Carnian. The sub-alkaline to alkaline basalts comprised in the volcano-sedimentary sequence (Volcano-sedimentary Complex) have a within-plate affinity. The volcanism occurs between the syn-rift and post-rift stages, and it is probably not linked to the passive margin evolution proper. The post-rift sequences are represented by the onset of the Pelagonian platform aggradation (''Pantokrator'' Carnian to Middle-Late? Jurassic) The northern passive margin sequence of Pelagonia (palaeogeographic sense) is interpreted as related to the Maliak ocean opening during the Early Mesozoic.

Current and future trens in the quality control of pharmaceuticals and biopharmaticals : impacts on Cost of Goods Sold (COGS)

[Summary] 2. Roles of quality control in the pharmaceutical and biopharmaceutical industries. - 2.1. Pharmaceutical industry. - 2.2. Biopharmaceutical industry. - 2.3. Policy and regulatory. - 2.3.1. The US Food and Drug Administration (FDA). - 2.3.2. The European Medicine Agency (EMEA). - 2.3.3. The Japanese Ministry of Work, Labor and Welfare (MHLW). - 2.3.4. The Swiss Agency for Therapeutic Products (Swissmedic). - 2.3.5. The International Conference on Harmonization (ICH). - - 3. Types of testing. - 3.1. Microbiological purity tests. - 3.2. Physiochemical tests. - 3.3. Critical to quality steps. - 3.3.1. API starting materials and excipients. - 3.3.2. Intermediates. - 3.3.3. APIs (drug substances) and final drug product. - 3.3.4. Primary and secondary packaging materials fro drug products. - - 4. Manufacturing cost and quality control. - 4.1.1. Pharmaceutical manufacturing cost breakdown. - 4.1.2. Biopharmaceutical manufacturing cost breakdown. - 4.2. Batch failure / rejection / rework / recalls. - - 5. Future trends in the quality control of pharmaceuticals and biopharmaceuticals. - 5.1. Rapid and real time testing. - 5.1.1. Physio-chemicals testing. - 5.1.2. Rapid microbiology methods